Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Compass leaves guidance unchanged despite strong H1, shares fall

(Sharecast News) - Compass Group saw shares fall on Wednesday after the contract caterer held on to full-year guidance, which points to a slight slowdown in underlying revenue and profit growth, despite a strong first half. On a statutory basis, revenues increased by 8.8% year-on-year to $22.6bn in the six months ended 31 March.

On an organic basis, the company reported 8.5% growth for the half year as a whole, with second quarter momentum easing from the 9.2% organic growth registered in the first quarter.

Underlying operating profits jumped by 11.6% year-on-year to $1.63bn, helped by a 10 basis-point improvement in the underlying operating margin to 7.2%.

However, the company still stuck with full-year guidance for organic revenue growth above 7.5% and high single-digit underlying operating profit growth.

Shares were down around 4% at 2,508p in early deals on Wednesday.

"With consensus forecasts already wandering into double-digit growth territory, there may be some disappointment if Compass doesn't serve up an upgrade alongside [the] half-year results," said Derren Nathan, head of equity analysis at Hargreaves Lansdown in a preview of the earnings last week.

Despite the market's disappointment at the results, chief executive Dominic Blakemore delivered a bullish outlook, saying: "The market opportunity is very attractive, with first-time outsourcing accounting for 45% of new business wins. Over the last 12 months, we have signed over $3.6bn of new contracts, an increase of 8.5% year on year, and we have a strong pipeline of future business across all our markets."

The company raised its interim dividend by 9.2% to 22.6 cents per share.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.